TRIM29

TRIM29 Full Name

tripartite motif containing 29

TRIM29 Introduction

Tripartite motif-containing 29 (TRIM29), also widely recognized in the scientific community as Ataxia Telangiectasia Group D Complementing gene (ATDC), is a unique and structurally distinct member of the tripartite motif (TRIM) family of proteins. While the vast majority of TRIM family members possess a classic tripartite architecture consisting of a RING finger, one or two B-boxes, and a coiled-coil domain, TRIM29 is notably characterized by the absence of the typical RING finger domain. Due to this structural deviation, it lacks the intrinsic E3 ubiquitin ligase activity typical of its family. Instead, TRIM29 functions primarily as a highly versatile scaffolding protein, utilizing its B-box and coiled-coil domains to facilitate complex protein-protein interactions and physically bridge various molecular components within the cell.

Functionally, TRIM29 exerts profound regulatory effects across a wide spectrum of fundamental cellular processes, acting as a pivotal modulator in both the nucleus and the cytoplasm. In the nucleus, it is deeply involved in the cellular DNA damage response and the regulation of apoptosis. By directly interacting with and sequestering the tumor suppressor protein p53, TRIM29 can inhibit p53-mediated transcriptional activities, thereby promoting cell survival and conferring cellular resistance to ionizing radiation and stress. In the cytoplasm, immunological research has highlighted TRIM29 as a critical negative regulator of the innate immune system. It plays an essential role in macrophages by targeting key signaling molecules for degradation via the recruitment of other E3 ligases, thereby tightly controlling the production of type I interferons and pro-inflammatory cytokines to prevent excessive, damaging immune responses.

Clinically, the aberrant expression and functional dysregulation of TRIM29 are intimately associated with the pathogenesis of numerous severe human diseases, most prominently cancer. In the context of oncology, TRIM29 typically acts as a potent oncogene. Its overexpression is frequently observed in a variety of aggressive malignancies, including pancreatic, lung, gastric, and ovarian cancers, where it actively drives tumor cell proliferation, survival, and invasion. In these cancers, TRIM29 strongly promotes the epithelial-mesenchymal transition (EMT) by upregulating signaling cascades like the Wnt/β-catenin pathway, facilitating widespread metastasis and correlating with poor patient prognosis. Beyond oncology, due to its dampening effect on macrophage activation, the dysregulation of TRIM29 is also increasingly implicated in the development of chronic inflammatory diseases and autoimmune disorders.

Figure 1. TRIM29 stimulates a number of oncologic pathways. (Source: Wu Q, et al. 2024)

Alternate Names for TRIM29

TRIM29; tripartite motif containing 29; tripartite motif-containing protein 29; ataxia telangiectasia group D associated protein; ATDC; FLJ36085; tripartite motif protein TRIM29; tripartite motif-containing 29; ataxia telangiectasia group D-associated protein; ataxia-telangiectasia group D-associated protein

• 1. Wu Q, et al. TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond. Cancer Metastasis Rev. 2024 Dec 7;44(1):16.
  2. Masuda Y, et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun. 2015 Jun 22;6:7299.